Investors sold shares of Hologic, Inc. (NASDAQ:HOLX) on strength during trading on Wednesday after an insider sold shares in the company. $14.89 million flowed into the stock on the tick-up and $34.06 million flowed out of the stock on the tick-down, for a money net flow of $19.17 million out of the stock. Of all companies tracked, Hologic had the 20th highest net out-flow for the day. Hologic traded up $0.28 for the day and closed at $40.88Specifically, Director Lawrence M. Levy sold 9,596 shares of the business’s stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Lawrence M. Levy sold 7,139 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $39.04, for a total value of $278,706.56. The disclosure for this sale can be found here. Insiders sold 35,972 shares of company stock worth $1,385,977 over the last quarter. 0.79% of the stock is currently owned by company insiders.

Several brokerages have issued reports on HOLX. BidaskClub lowered Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Needham & Company LLC reaffirmed a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. Deutsche Bank AG lowered their target price on Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) lowered Hologic from a “conviction-buy” rating to a “buy” rating and lowered their target price for the stock from $48.00 to $47.00 in a research report on Thursday, August 3rd. Finally, Royal Bank Of Canada lowered their target price on Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $47.54.

The stock has a market capitalization of $11,585.71, a PE ratio of 19.90, a P/E/G ratio of 1.94 and a beta of 0.93. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. The firm had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.52 EPS. equities research analysts predict that Hologic, Inc. will post 2.12 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC bought a new position in Hologic in the 3rd quarter valued at $618,000. GSA Capital Partners LLP grew its stake in Hologic by 379.5% in the 3rd quarter. GSA Capital Partners LLP now owns 63,760 shares of the medical equipment provider’s stock valued at $2,339,000 after purchasing an additional 50,463 shares during the period. Americafirst Capital Management LLC bought a new position in Hologic in the 3rd quarter valued at $554,000. IFM Investors Pty Ltd bought a new position in Hologic in the 3rd quarter valued at $335,000. Finally, Ladenburg Thalmann Financial Services Inc. grew its stake in Hologic by 66.4% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,487 shares of the medical equipment provider’s stock valued at $458,000 after purchasing an additional 4,984 shares during the period. Hedge funds and other institutional investors own 97.72% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/investors-sell-shares-of-hologic-inc-holx-on-strength-on-insider-selling/1720346.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.